• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Exact Sciences Corporation

    3/23/26 9:41:58 AM ET
    $EXAS
    Medical Specialities
    Health Care
    Get the next $EXAS alert in real time by email
    S-8 POS 1 d128896ds8pos.htm S-8 POS S-8 POS

    As filed with the Securities and Exchange Commission on March 23, 2026

    Registration Nos. 333-273572

    333-288639

    333-266471

    333-251900

    333-234608

    333-219553

    333-232916

    333-229780

    333-212730

    333-211099

    333-207703

    333-190350

    333-168909

    333-164467

    333-158307

    333-141323

    333-123584

    333-107840

    333-54618

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    POST-EFFECTIVE AMENDMENT NO. 1 TO

    Form S-8 Registration Statement No. 333-288639

    Form S-8 Registration Statement No. 333-266471

    Form S-8 Registration Statement No. 333-251900

    Form S-8 Registration Statement No. 333-234608

    Form S-8 Registration Statement No. 333-232916

    Form S-8 Registration Statement No. 333-229780

    Form S-8 Registration Statement No. 333-212730

    Form S-8 Registration Statement No. 333-211099

    Form S-8 Registration Statement No. 333-207703

    Form S-8 Registration Statement No. 333-190350

    Form S-8 Registration Statement No. 333-168909

    Form S-8 Registration Statement No. 333-164467

    Form S-8 Registration Statement No. 333-158307

    Form S-8 Registration Statement No. 333-141323

    Form S-8 Registration Statement No. 333-123584

    Form S-8 Registration Statement No. 333-54618

    POST-EFFECTIVE AMENDMENT NO. 2 TO

    Form S-8 Registration Statement No. 333-273572

    Form S-8 Registration Statement No. 333-219553

    Form S-8 Registration Statement No. 333-107840

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Exact Sciences Corporation

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   02-0478229
    (State or other jurisdiction of incorporation)   (I.R.S. Employer Identification No.)

    100 Abbott Park Road

    Abbott Park, Illinois 60064-6400

    (Address of Principal Executive Offices) (Zip Code)

    Exact Sciences Corporation 2025 Omnibus Long-Term Incentive Plan

    Exact Sciences Corporation 2019 Omnibus Long-Term Incentive Plan

    Exact Sciences Corporation 2010 Omnibus Long-Term Incentive Plan (as amended and restated effective July 27, 2017)

    Exact Sciences Corporation 2010 Omnibus Long-Term Incentive Plan (as amended and restated effective April 28, 2015)

    Exact Sciences Corporation 2010 Employee Stock Purchase Plan (as amended and restated on July 31, 2024)

    Amended and Restated Exact Sciences Corporation 2010 Employee Stock Purchase Plan

    Exact Sciences Corporation 401(k) Plan

    Thrive Earlier Detection Corp. 2019 Stock Option and Grant Plan

    Genomic Health, Inc. Amended and Restated 2005 Stock Incentive Plan, as assumed by the Registrant

    Exact Sciences Corporation 2010 Employee Stock Purchase Plan

    Exact Sciences Corporation 2016 Inducement Award Plan

    Exact Sciences Corporation 2015 Inducement Award Plan

    Exact Sciences Corporation 2010 Omnibus Long-Term Incentive Plan

    2000 Stock Option and Incentive Plan

    2000 Employee Stock Purchase Plan

    Amended and Restated 2000 Employee Stock Purchase Plan

    1995 Stock Option Plan

    (Full title of the plan)

     

     

    James R. Wenner

    Vice President and Treasurer

    Abbott Laboratories

    100 Abbott Park Road

    Abbott Park, Illinois 60064-6400

    (Name and address of agent for service)

    (224) 667-6100

    (Telephone number, including area code, of agent for service)

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. ☐

     

     
     


    DEREGISTRATION OF SECURITIES

    This Post-Effective Amendment, filed by Exact Sciences Corporation, a Delaware corporation (the “Registrant”), relates to the following registration statements on Form S-8 (collectively, the “Registration Statements”), filed with the U.S. Securities and Exchange Commission (the “SEC”) by the Registrant:

     

      •  

    Registration Statement No. 333-273572, filed with the SEC on August 1, 2023 and amended on July 11, 2025, pertaining to the registration of 4,340,000 shares of the Registrant’s common stock issuable pursuant to the Exact Sciences Corporation 2019 Omnibus Long-Term Incentive Plan (the “2019 Plan”). The Registration Statement also covers shares of the Registrant’s common stock subject to stock options or other awards granted under the Exact Sciences Corporation 2010 Omnibus Long-Term Incentive Plan (As Amended and Restated Effective July 27, 2017) and the 2019 Plan as of June 12, 2025 that expire or are terminated, surrendered or forfeited for any reason without the issuance of shares of the Registrant’s common stock.

     

      •  

    Registration Statement No. 333-288639, filed with the SEC on July 11, 2025, pertaining to the registration of (i) 11,735,501 shares of the Registrant’s common stock issuable pursuant to the Exact Sciences Corporation 2025 Omnibus Long-Term Incentive Plan, and (ii) 4,000,000 shares of the Registrant’s common stock issuable pursuant to the Exact Sciences Corporation 2010 Employee Stock Purchase Plan (as amended and restated on July 31, 2024).

     

      •  

    Registration Statement No. 333-266471, filed with the SEC on August 2, 2022, pertaining to the registration of (i) 14,000,000 shares of the Registrant’s common stock issuable pursuant to the 2019 Plan, (ii) 3,000,000 shares of the Registrant’s common stock issuable pursuant to the Amended and Restated Exact Sciences Corporation 2010 Employee Stock Purchase Plan, and (iii) 3,000,000 shares of the Registrant’s common stock issuable pursuant to the Exact Sciences Corporation 401(k) Plan (the “401(k) Plan”).

     

      •  

    Registration Statement No. 333-251900, filed with the SEC on January 5, 2021, pertaining to the registration of 1,635,871 shares of the Registrant’s common stock issuable upon exercise or settlement, as applicable, of certain equity awards issued under the Thrive Earlier Detection Corp. 2019 Stock Option and Grant Plan and assumed by the Registrant.

     

      •  

    Registration Statement No. 333-234608, filed with the SEC on November 8, 2019, pertaining to the registration of (i) 1,093,874 shares of the Registrant’s common stock issuable upon future settlement of certain awards issued under the Genomic Health, Inc. Amended and Restated 2005 Stock Incentive Plan, as assumed by the Registrant (the “2005 Genomic Health Plan”) and converted into corresponding awards in respect of the Registrant’s common stock, and (ii) 1,889,064 shares of the Registrant’s common stock being transferred from the 2005 Genomic Health Plan to the 2019 Plan for future issuance thereunder.

     

      •  

    Registration Statement No. 333-219553, filed with the SEC on July 28, 2017 and amended on July 31, 2019, pertaining to the registration of 12,700,000 shares of the Registrant’s common stock issuable pursuant to the Exact Sciences Corporation 2010 Omnibus Long-Term Incentive Plan (As Amended and Restated Effective April 28, 2015), as amended. The Registration Statement also covers shares of the Registrant’s common stock subject to stock options or other awards granted under the Exact Sciences Corporation 2010 Omnibus Long-Term Incentive Plan (As Amended and Restated Effective July 27, 2017) as of July 25, 2019 that expire or are terminated, surrendered or forfeited for any reason without the issuance of shares of the Registrant’s common stock.

     

      •  

    Registration Statement No. 333-232916, filed with the SEC on July 31, 2019, pertaining to the registration of 13,829,582 shares of the Registrant’s common stock issuable pursuant to the 2019 Plan.

     

      •  

    Registration Statement No. 333-229780, filed with the SEC on February 21, 2019, pertaining to the registration of 1,000,000 shares of the Registrant’s common stock issuable pursuant to the 401(k) Plan.

     

      •  

    Registration Statement No. 333-212730, filed with the SEC on July 28, 2016, pertaining to the registration of 2,000,000 shares of the Registrant’s common stock issuable pursuant to the Exact Sciences Corporation 2010 Employee Stock Purchase Plan, as amended.

     

    1


      •  

    Registration Statement No. 333-211099, filed with the SEC on May 3, 2016, pertaining to the registration of (i) 500,000 shares of the Registrant’s common stock issuable pursuant to the Exact Sciences Corporation 2010 Employee Stock Purchase Plan, as amended, and (ii) 1,300,000 shares of the Registrant’s common stock issuable pursuant to the Exact Sciences Corporation 2016 Inducement Award Plan.

     

      •  

    Registration Statement No. 333-207703, filed with the SEC on October 30, 2015, pertaining to the registration of (i) 8,360,000 shares of the Registrant’s common stock issuable pursuant to the Exact Sciences Corporation 2010 Omnibus Long-Term Incentive Plan (As Amended and Restated Effective April 28, 2015), and (ii) 315,000 shares of the Registrant’s common stock issuable pursuant to the Exact Sciences Corporation 2015 Inducement Award Plan.

     

      •  

    Registration Statement No. 333-190350, filed with the SEC on August 2, 2013, pertaining to the registration of 2,800,000 shares of the Registrant’s common stock issuable pursuant to the Exact Sciences Corporation 2010 Omnibus Long-Term Incentive Plan.

     

      •  

    Registration Statement No. 333-168909, filed with the SEC on August 17, 2010, pertaining to the registration of (i) 4,400,000 shares of the Registrant’s common stock issuable pursuant to the Exact Sciences Corporation 2010 Omnibus Long-Term Incentive Plan, and (ii) 300,000 shares of the Registrant’s common stock issuable pursuant to the Exact Sciences Corporation 2010 Employee Stock Purchase Plan.

     

      •  

    Registration Statement No. 333-164467, filed with the SEC on January 22, 2010, pertaining to the registration of 250,000 shares of the Registrant’s common stock issuable pursuant to the 401(k) Plan.

     

      •  

    Registration Statement No. 333-158307, filed with the SEC on March 31, 2009, pertaining to the registration of 1,376,147 shares of the Registrant’s common stock issuable pursuant to the 2000 Stock Option and Incentive Plan.

     

      •  

    Registration Statement No. 333-141323, filed with the SEC on March 15, 2007, pertaining to the registration of 1,343,168 shares of the Registrant’s common stock issuable pursuant to the 2000 Stock Option and Incentive Plan.

     

      •  

    Registration Statement No. 333-123584, filed with the SEC on March 25, 2005, pertaining to the registration of (i) 2,744,000 shares of the Registrant’s common stock issuable pursuant to the 2000 Stock Option and Incentive Plan, and (ii) 341,940 shares of the Registrant’s common stock issuable pursuant to the 2000 Employee Stock Purchase Plan.

     

      •  

    Registration Statement No. 333-107840, filed with the SEC on August 11, 2003 and amended on August 18, 2003, pertaining to the registration of (i) 1,952,690 shares of the Registrant’s common stock issuable pursuant to the 2000 Stock Option and Incentive Plan, and (ii) 283,962 shares of the Registrant’s common stock issuable pursuant to the Amended and Restated 2000 Employee Stock Purchase Plan.

     

      •  

    Registration Statement No. 333-54618, filed with the SEC on January 30, 2001, pertaining to the registration of (i) 1,833,496 shares of the Registrant’s common stock issuable pursuant to the 1995 Stock Option Plan, (ii) 1,000,000 shares of the Registrant’s common stock issuable pursuant to the 2000 Stock Option and Incentive Plan, and (iii) 300,000 shares of the Registrant’s common stock issuable pursuant to the 2000 Employee Stock Purchase Plan.

    The Registrant is filing this post-effective amendment to the Registration Statements to withdraw and remove from registration the registered but unsold securities issuable by the Registrant pursuant to the Registration Statements.

     

    2


    On March 23, 2026, the Registrant was acquired by Abbott Laboratories, an Illinois corporation (“Parent”), pursuant to the Agreement and Plan of Merger, dated as of November 19, 2025 (the “Merger Agreement”), by and among Parent, the Registrant, and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent. Pursuant to the Merger Agreement, Merger Sub merged with and into the Registrant (the “Merger”), with the Registrant continuing as the surviving corporation and a direct, wholly owned subsidiary of Parent.

    As a result of the Merger, the offerings of the Registrant’s securities pursuant to the Registration Statements have been terminated. In accordance with the undertakings made by the Registrant in the Registration Statements to remove from registration, by means of a post-effective amendment, any of the securities being registered which remain unsold at the termination of the offerings, the Registrant hereby removes from registration the securities registered but unsold under the Registration Statements. The Registration Statements are hereby amended, as appropriate, to reflect the deregistration of such securities.

     

    3


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment to the Registration Statements on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Abbott Park, State of Illinois, on March 23, 2026.

     

    Exact Sciences Corporation

    By:

     

    /s/ James R. Wenner

     

    James R. Wenner

     

    Vice President and Treasurer

    Pursuant to Rule 478 under the Securities Act of 1933, as amended, no other person is required to sign this Post-Effective Amendment.

    Get the next $EXAS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EXAS

    DatePrice TargetRatingAnalyst
    1/20/2026$105.00Outperform → Neutral
    Mizuho
    1/5/2026$105.00Outperform → In-line
    Evercore ISI
    4/10/2025$60.00Outperform
    Mizuho
    3/13/2025$52.00Sector Perform
    RBC Capital Mkts
    1/23/2025$70.00Overweight
    Barclays
    8/28/2024$75.00Overweight
    Wells Fargo
    6/27/2024$70.00Sector Outperform
    Scotiabank
    6/3/2024$75.00Buy
    Jefferies
    More analyst ratings

    $EXAS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Conroy Kevin T bought $1,001,325 worth of shares (19,500 units at $51.35), increasing direct ownership by 2% to 1,074,191 units (SEC Form 4)

    4 - EXACT SCIENCES CORP (0001124140) (Issuer)

    11/13/24 12:56:28 PM ET
    $EXAS
    Medical Specialities
    Health Care

    $EXAS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $EXAS
    SEC Filings

    View All

    Exact Sciences to Present New Molecular Residual Disease and Multi-Cancer Early Detection Data at AACR 2026

    The Oncodetect® test expands the role of tumor-informed MRD in triple-negative breast cancer The Cancerguard® test demonstrates improved early-stage multi-cancer detection performance Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced four presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting highlighting new data in molecular residual disease (MRD) testing and multi-cancer early detection (MCED). The meeting will take place from April 17–22, 2026, in San Diego, CA. Exact Sciences will present new findings from the NSABP B-59/GBG-96-GeparDouze trial evaluating its tumor-informed circulatin

    3/17/26 4:31:00 PM ET
    $EXAS
    Medical Specialities
    Health Care

    Exact Sciences Named Gallup Exceptional Workplace Award Winner for Third Consecutive Year

    Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced it has earned the 2026 Gallup Exceptional Workplace Award (GEWA), marking the third consecutive year the company has received this prestigious recognition. The award honors organizations with some of the most engaged workplace cultures in the world. Gallup recognized Exact Sciences for fostering a culture where employees feel valued and connected to the company's mission, enabling strong performance even during periods of change and complexity. "Our people are the heart of Exact Sciences," said Sarah Condella, executive vice president of human resources. "This recognition bel

    3/4/26 9:00:00 AM ET
    $EXAS
    Medical Specialities
    Health Care

    Marking National Colorectal Cancer Awareness Month, Privia Health Program Achieves 84% Colorectal Cancer Screening Rate Through Industry Collaboration

    Amalgam Rx, Inc., Privia Health, and Exact Sciences Corp. highlight how coordinated, EHR-enabled patient outreach supported measurable screening impact at scale. Amalgam Rx, Inc., a leader in data-driven, AI-powered healthcare engagement and clinical decision support, today announced results from a Privia Health (NASDAQ:PRVA)-led colorectal cancer (CRC) screening program, supported by Amalgam Rx, Inc. and Exact Sciences Corp. (NASDAQ:EXAS). Documented in a published Privia Health case study, the program demonstrates how EHR-integrated workflows and proactive patient outreach supported an increase of CRC screening rates to 84% in 2024, exceeding national benchmarks and surpassing the Natio

    3/3/26 10:00:00 AM ET
    $EXAS
    $PRVA
    Medical Specialities
    Health Care
    Medical/Nursing Services

    SEC Form POSASR filed by Exact Sciences Corporation

    POSASR - EXACT SCIENCES CORP (0001124140) (Filer)

    3/23/26 9:47:32 AM ET
    $EXAS
    Medical Specialities
    Health Care

    SEC Form S-8 POS filed by Exact Sciences Corporation

    S-8 POS - EXACT SCIENCES CORP (0001124140) (Filer)

    3/23/26 9:44:07 AM ET
    $EXAS
    Medical Specialities
    Health Care

    SEC Form S-8 POS filed by Exact Sciences Corporation

    S-8 POS - EXACT SCIENCES CORP (0001124140) (Filer)

    3/23/26 9:41:58 AM ET
    $EXAS
    Medical Specialities
    Health Care

    $EXAS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Baranick Brian

    4 - EXACT SCIENCES CORP (0001124140) (Issuer)

    3/23/26 9:21:24 AM ET
    $EXAS
    Medical Specialities
    Health Care

    SEC Form 4 filed by Herriott James

    4 - EXACT SCIENCES CORP (0001124140) (Issuer)

    3/23/26 9:20:51 AM ET
    $EXAS
    Medical Specialities
    Health Care

    SEC Form 4 filed by Bloomer Aaron

    4 - EXACT SCIENCES CORP (0001124140) (Issuer)

    3/23/26 9:20:41 AM ET
    $EXAS
    Medical Specialities
    Health Care

    $EXAS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Exact Sciences downgraded by Mizuho with a new price target

    Mizuho downgraded Exact Sciences from Outperform to Neutral and set a new price target of $105.00

    1/20/26 9:08:04 AM ET
    $EXAS
    Medical Specialities
    Health Care

    Exact Sciences downgraded by Evercore ISI with a new price target

    Evercore ISI downgraded Exact Sciences from Outperform to In-line and set a new price target of $105.00

    1/5/26 8:47:19 AM ET
    $EXAS
    Medical Specialities
    Health Care

    Mizuho initiated coverage on Exact Sciences with a new price target

    Mizuho initiated coverage of Exact Sciences with a rating of Outperform and set a new price target of $60.00

    4/10/25 12:41:36 PM ET
    $EXAS
    Medical Specialities
    Health Care

    $EXAS
    Leadership Updates

    Live Leadership Updates

    View All

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN

    SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott will join its Board of Directors on March 20, 2025. The Company further announced that Ryan Trimble—after 14 years serving Sera, its customers and its shareholders—has informed the Company of his intention to retire and step down as a director effective June 30, 2025 as part of the Board's ongoing efforts to refresh its composition, expertise and experience. Marcus Wilson also informed the Company that, as part of that same

    3/19/25 4:10:00 PM ET
    $EXAS
    $QTRX
    $SERA
    Medical Specialities
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $EXAS
    Financials

    Live finance-specific insights

    View All

    Exact Sciences Announces Record Fourth Quarter and Full Year 2025 Results

    Fourth quarter and 2025 highlights Total fourth quarter revenue of $878 million, an increase of 23% on a reported and core revenue basis, with Screening revenue of $695 million and Precision Oncology revenue of $183 million Total 2025 revenue of $3.25 billion, an increase of 18% on a reported and core revenue basis, with Screening revenue of $2.53 billion and Precision Oncology revenue of $717 million Operating cash flow was $491 million and free cash flow was $357 million for the full-year 2025, an improvement of 133% and 379%, respectively Net loss was $208 million and adjusted EBITDA was $400 million for the full-year 2025, an improvement of $821 million and $77 million, resp

    2/13/26 4:05:00 PM ET
    $EXAS
    Medical Specialities
    Health Care

    Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments

    Acquisition adds a new growth vertical to Abbott's already high single-digit growth profile, gaining leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics segmentsAcquisition will uniquely position Abbott to transform cancer care, advancing earlier detection and optimizing treatment and monitoring to help millions more people live healthier livesExact Sciences' product lines feature advanced cancer screening and diagnostic solutions, including the market-leading Cologuard® and Oncotype DX® tests, and cutting-edge liquid biopsy tests for multi-cancer early detection and molecular residual disease testingAcquisition will be immediately accretive to

    11/20/25 7:30:00 AM ET
    $ABT
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities

    Exact Sciences Announces Third Quarter 2025 Results

    Reports record revenue, raises full-year guidance, generates record cash from operations Third quarter and recent highlights Delivered record total third quarter revenue of $851 million, an increase of 20% on a reported and core revenue basis, including Screening revenue of $666 million and Precision Oncology revenue of $184 million Raised full-year 2025 revenue and adjusted EBITDA guidance midpoints by $78 million and $10 million, respectively Generated record cash from operations and free cash flow Launched Cancerguard®, the company's multi-cancer early detection test, for patients in the United States Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer scree

    11/3/25 4:05:00 PM ET
    $EXAS
    Medical Specialities
    Health Care

    $EXAS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Exact Sciences Corporation

    SC 13G - EXACT SCIENCES CORP (0001124140) (Subject)

    11/13/24 2:58:53 PM ET
    $EXAS
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Exact Sciences Corporation

    SC 13G/A - EXACT SCIENCES CORP (0001124140) (Subject)

    11/8/24 10:52:39 AM ET
    $EXAS
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Exact Sciences Corporation

    SC 13G - EXACT SCIENCES CORP (0001124140) (Subject)

    10/7/24 11:37:08 AM ET
    $EXAS
    Medical Specialities
    Health Care